ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Lilly Links With United Therapeutics

by Lisa M. Jarvis
November 24, 2008 | APPEARED IN VOLUME 86, ISSUE 47

United Therapeutics has agreed to pay Eli Lilly & Co. $150 million for U.S. rights to sell Lilly's molecule tadalafil as a treatment for pulmonary arterial hypertension (PAH), a rare blood vessel disorder. Lilly already markets tadalafil to treat erectile dysfunction under the brand name Cialis, and it has filed for regulatory approval to use the drug to treat PAH in North America, Japan, and Europe. Lilly, meanwhile, will buy $150 million in United Therapeutics stock and will manufacture and supply the drug. United Therapeutics already markets Remodulin for the treatment of PAH.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment